XI International Meeting on Paracoccidioidomycosis

XI International Meeting on Paracoccidioidomycosis

Resume:131-2

Poster (Painel)

131-2	Treatment of experimental chromoblastomycosis using DNA vaccine (DNA-hsp65) alone, or in association with intraconazole and amphotericin B intralesionally
Authors:	Isaque Medeiros Siqueira (UNB - Universidade de Brasília) ; Yanna Karla de Medeiros Nóbrega (UNB - Universidade de Brasília) ; Karina Smidt Simon (UNB - Universidade de Brasília) ; Ana Camila Oliveira Souza (UNB - Universidade de Brasília) ; Márcio Souza Jerônimo (UNB - Universidade de Brasília) ; Anamélia Lorenzetti Bocca (UNB - Universidade de Brasília)

Abstract

Chromoblastomycosis (CBM) is a chronic worldwide subcutaneous mycosis, caused by several dimorphic, pigmented dematiaceous fungi among which Fonsecaea pedrosoi is the major causative agent in Brazil. It is a chronic granulomatous fungal infection usually observed in the skin and subcutaneous tissue. The natural niche of F. pedrosoi is the soil, rotten wood and decomposing plant material. Patients with the disease are still considered as therapeutic challenge, mainly due to its recalcitrant nature. There is no treatment of choice for this neglected mycosis, but rather several treatment options. Itraconazole and terbinafine showed the best results in treating the disease, although the healing of severe cases is still uncommon. However, several studies have reported the DNA vaccine as promising in the treatment of fungal infections, which allow the host to restore depressed cellular immunity, minimizing the toxic effects from conventional antifungal therapies. In this matter, this work was conducted aiming the development of new therapies, including DNA-hsp65 vaccine. Rats (rattus norvegicus albinus) were infected with Fonsecaea pedrosoi propagules and then treated with DNA-hsp65 naked, alone or in association with intraconazole and amphotericin B, intralesionally. After 30, 60 and 90 days they were sacrificed and by analyzing the morfometrical and histopathological aspects, also the recovery/quantification of colony forming units, the results showed that treatment regimen using itraconazole and amphotericin B, intralesionally, was effective in treating experimental CBM, as well as therapy using naked DNA-hsp65 vaccine. It also has been shown that chemotherapy associated with DNA-hsp65 vaccine is efficient in the treatment of experimental CBM, accelerating the healing process of the disease, becoming able to tone down the toxic effects from prolonged chemotherapy.

Keyword: chromoblastomycosis, experimental model, DNA vaccine, DNA-hsp65

਀�